Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113594 · ClinicalTrials.gov registry record · Phase 3
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00113594 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 100 participants.
The verdict
NCT00113594, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize olanzapine pharmacokinetics: the inter- and intra- subject variabilities of olanzapine pharmacokinetics; and the potential influence of patient factors such as age, weight, gender, origin, and smoking status on olanzapine pharmacokinetics in adolescents with schizophrenia or bipolar I disorder. This study will also assess the safety of olanzapine delivered orally.
Interventions
- DRUG Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113594
The ClinicalTrials.gov registry entry for NCT00113594 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olanzapine is the first listed.
NCT00113594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113594 about?
NCT00113594 is a clinical study titled "Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder". The purpose of this study is to characterize olanzapine pharmacokinetics: the inter- and intra- subject variabilities of olanzapine pharmacokinetics; and the potential influence of patient factors such as age, weight, gender, origin, and smoking status on olanzapine pharmacokinetics in adolescents w...
What is the current status of trial NCT00113594?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2005-06. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00113594?
The interventions under investigation include: Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00113594?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.